Literature DB >> 33338403

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.

Fran Robson, Khadija Shahed Khan, Thi Khanh Le, Clément Paris, Sinem Demirbag, Peter Barfuss, Palma Rocchi, Wai-Lung Ng.   

Abstract

Entities:  

Year:  2020        PMID： 33338403     DOI： 10.1016/j.molcel.2020.11.048

Source DB:  PubMed          Journal:  Mol Cell        ISSN： 1097-2765            Impact factor:   17.970


× No keyword cloud information.
  18 in total

1.  Clinically observed deletions in SARS-CoV-2 Nsp1 affect its stability and ability to inhibit translation.

Authors:  Pravin Kumar; Erin Schexnaydre; Karim Rafie; Tatsuaki Kurata; Ilya Terenin; Vasili Hauryliuk; Lars-Anders Carlson
Journal:  FEBS Lett       Date:  2022-04-25       Impact factor: 3.864

2.  Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective.

Authors:  Miao Miao; Erik De Clercq; Guangdi Li
Journal:  Biomedicines       Date:  2021-04-11

Review 3.  mRNA vaccines for COVID-19: what, why and how.

Authors:  Jung Woo Park; Philip N P Lagniton; Yu Liu; Ren-He Xu
Journal:  Int J Biol Sci       Date:  2021-04-10       Impact factor: 6.580

4.  The Roles of APOBEC-mediated RNA Editing in SARS-CoV-2 Mutations, Replication and Fitness.

Authors:  Kyumin Kim; Peter Calabrese; Shanshan Wang; Chao Qin; Youliang Rao; Pinghui Feng; Xiaojiang S Chen
Journal:  bioRxiv       Date:  2022-04-07

5.  SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection.

Authors:  Dina Khateeb; Tslil Gabrieli; Bar Sofer; Adi Hattar; Sapir Cordela; Abigael Chaouat; Ilia Spivak; Izabella Lejbkowicz; Ronit Almog; Michal Mandelboim; Yotam Bar-On
Journal:  PLoS Pathog       Date:  2022-01-12       Impact factor: 6.823

6.  HiSpike Method for High-Throughput Cost Effective Sequencing of the SARS-CoV-2 Spike Gene.

Authors:  Ephraim Fass; Gal Zizelski Valenci; Mor Rubinstein; Paul J Freidlin; Shira Rosencwaig; Inna Kutikov; Robert Werner; Nofar Ben-Tovim; Efrat Bucris; Oran Erster; Neta S Zuckerman; Orna Mor; Ella Mendelson; Zeev Dveyrin; Efrat Rorman; Israel Nissan
Journal:  Front Med (Lausanne)       Date:  2022-01-11

7.  Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains.

Authors:  Ting Pan; Zhongwei Hu; Fengyu Hu; Yiwen Zhang; Bingfeng Liu; Changwen Ke; Qiumin She; Xin He; Xiaoping Tang; Hui Zhang
Journal:  Cell Mol Immunol       Date:  2021-10-11       Impact factor: 11.530

8.  SARS-CoV-2 Nsp14 activates NF-κB signaling and induces IL-8 upregulation.

Authors:  Taiwei Li; Adam D Kenney; Helu Liu; Guillaume N Fiches; Dawei Zhou; Ayan Biswas; Jianwen Que; Netty Santoso; Jacob S Yount; Jian Zhu
Journal:  bioRxiv       Date:  2021-05-26

9.  Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation.

Authors:  S A Kemp; D A Collier; R Datir; Iatm Ferreira; S Gayed; A Jahun; M Hosmillo; C Rees-Spear; P Mlcochova; Ines Ushiro Lumb; David J Roberts; Anita Chandra; N Temperton; K Sharrocks; E Blane; Jag Briggs; Gils Mj van; Kgc Smith; J R Bradley; C Smith; R Doffinger; L Ceron-Gutierrez; G Barcenas-Morales; D D Pollock; R A Goldstein; A Smielewska; J P Skittrall; T Gouliouris; I G Goodfellow; E Gkrania-Klotsas; Cjr Illingworth; L E McCoy; R K Gupta
Journal:  medRxiv       Date:  2020-12-29

10.  Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes.

Authors:  Debashree Chatterjee; Alexandra Tauzin; Annemarie Laumaea; Shang Yu Gong; Yuxia Bo; Aurélie Guilbault; Guillaume Goyette; Catherine Bourassa; Gabrielle Gendron-Lepage; Halima Medjahed; Jonathan Richard; Sandrine Moreira; Marceline Côté; Andrés Finzi
Journal:  Viruses       Date:  2022-01-14       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.